Tutti gli studi
Attivo ma non reclutanteFASE4INTERVENTISTICO

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

This research study is for people aged 12 and older who have hereditary angioedema, a rare condition causing swelling attacks. The main goal is to check the safety of a new treatment called garadacimab. Participants will switch to garadacimab from their current regular preventative medicine for HAE. This could be a kallikrein inhibitor or a medicine derived from human plasma. The study will look at how people respond when they take garadacimab once a month for about three months. It's a 'Phase 4' study, meaning the medicine is already approved for some uses, and researchers are gathering more information on its safety when used in a new way or by a new group of people. This helps doctors understand if it's a good alternative for patients.

A colpo d'occhio

Stato
Attivo ma non reclutante
Fase
FASE4
Sponsor
CSL Behring
Obiettivo di iscrizione
18
Inizio
28 Apr 2025
Completamento stimato
23 giu 2026

Di cosa tratta questo studio?

This study is about a medicine called garadacimab and its safety for people who have hereditary angioedema (HAE). HAE is a condition that causes sudden, painful swelling in different parts of the body, like the face, hands, feet, or tummy. This swelling can be quite severe and sometimes life-threatening. Many people with HAE take regular medicines to try and prevent these attacks from happening; these are called 'preventative' or 'prophylactic' treatments.

In this study, researchers want to see what happens when people who are already taking one of these regular preventative HAE medicines switch to garadacimab. They are particularly interested in how safe this switch is and how well people tolerate the new medicine. Garadacimab will be given once a month for around three months to see its effects.

This kind of study, called a 'Phase 4' study, usually happens after a medicine has already been approved and is available. It helps doctors and researchers learn more about the medicine in real-world settings, especially when patients change from one treatment to another. Understanding the safety of switching treatments is important for doctors to help their patients manage HAE effectively.

Punti chiave

  • This study is for people aged 12 and over with hereditary angioedema (HAE).
  • It researches the safety of switching to a medicine called garadacimab.
  • Participants will take garadacimab once a month for about three months.
  • It’s for people already using another preventative HAE treatment.
  • Understanding treatment switches helps doctors improve HAE care.

Chi può essere idoneo?

To join this study, you must be at least 12 years old. You need to have a clear diagnosis of hereditary angioedema (HAE), type 1 or type 2. This diagnosis should be confirmed by your doctor's records, including showing you have the right symptoms and specific blood test results that indicate HAE. Your medical history should also show that on-demand treatments (medicines taken during an attack) have worked for you in the past.

You should currently be taking a regular preventative medicine for your HAE, such as lanadelumab, berotralstat, or a plasma-derived C1-esterase inhibitor. You must have been on a steady dose of this medicine for at least three months before the study starts. This helps researchers see how the switch to garadacimab affects you, rather than changes in your old medicine.

There are also reasons why you might not be able to join. For example, if you have another type of angioedema alongside HAE, or if you're taking certain other medicines (like androgens or antifibrinolytics) to prevent HAE attacks. You also can't join if you're allergic to garadacimab.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Are you 12 years old or older?
  2. Do you have a confirmed diagnosis of hereditary angioedema (HAE)?
  3. Are you currently taking a regular preventative medicine for your HAE?
  4. Have you been on a stable dose of this medicine for at least three months?
  5. Have your on-demand HAE treatments worked for you in the past?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to take part in this study, you will first go through a screening process to make sure you are suitable. Once confirmed, you will switch from your current HAE preventative medicine to the study medicine, garadacimab. You will receive garadacimab once a month for about three months. This will involve regular visits to the clinic where you will have health checks, blood tests, and doctors will ask about your HAE attacks and any side effects you might experience. The total duration of your participation in the study, from your initial checks to your final follow-up, will be clearly explained to you by the study team.

Rischi e benefici potenziali

Participating in this study might offer potential benefits, such as trying a new preventative treatment for your HAE, which could potentially work well for you. However, as with any medicine, there are also potential risks, including side effects from garadacimab or feeling unwell as you switch from your current medication. All known risks will be clearly explained to you by the study team. Remember, taking part is completely voluntary, and you are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Luoghi (11)

  • Research Solutions of Arizona
    Codice postale verificato
    Litchfield Park, United States
  • Allergy and Asthma Clinic of Northwest Arkansas
    Codice postale verificato
    Bentonville, United States
  • Donald Levy M.D.
    Codice postale verificato
    Orange, Stati Uniti
  • Raffi Tachdjian MD, Inc.
    Codice postale verificato
    Santa Monica, United States
  • Bernstein Clinical Research Center, LLC
    Codice postale verificato
    Cincinnati, Stati Uniti
  • Chronicle Bio
    Codice postale verificato
    West Valley City, United States
  • McMaster University-Hamilton
    Codice postale verificato
    Hamilton, Canada
  • Montreal Clinical Research Institute
    Codice postale verificato
    Montreal, Canada
  • Clinique Spécialisée en Allergie de la Capitale
    Codice postale verificato
    Québec, Canada
  • HZRM Hämophilie Zentrum Rhein Main GmbH
    Codice postale verificato
    Francoforte, Germania
  • Hautklinik und Poliklinik der Universitätsklinik Mainz
    Codice postale verificato
    Magonza, Germania

Domande comuni

What is hereditary angioedema (HAE)?

HAE is a rare genetic condition that causes sudden and unpredictable swelling attacks, often in the face, hands, feet, tummy, or throat.

What is garadacimab?

Garadacimab is a medicine being studied to help prevent HAE attacks.

Why is this study happening?

This study aims to find out how safe it is for people with HAE to switch from their current preventative medicine to garadacimab.

Chi può partecipare a questo studio?

People aged 12 and over with HAE who are currently taking another regular medicine to prevent their HAE attacks could be eligible.

Quanto durerà lo studio per me?

If you join, you would take garadacimab once a month for about three months as part of the study.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.